DB:8NN

Stock Analysis Report

Executive Summary

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for haematological cancers.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Nordic Nanovector's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8NN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

8NN

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-76.6%

8NN

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 8NN underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 8NN underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

8NNIndustryMarket
7 Day1.6%11.7%9.9%
30 Day-37.2%-5.9%-16.6%
90 Day-66.9%-22.6%-24.8%
1 Year-76.6%-76.6%-7.9%-8.1%-15.0%-17.5%
3 Year-88.2%-88.2%16.6%15.4%-17.4%-24.5%
5 Year-74.8%-74.8%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Nordic Nanovector's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nordic Nanovector undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8NN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8NN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8NN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 8NN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8NN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8NN is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Nordic Nanovector forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

22.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8NN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8NN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8NN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8NN's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 8NN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 8NN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Nordic Nanovector performed over the past 5 years?

-25.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8NN is currently unprofitable.

Growing Profit Margin: 8NN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8NN is unprofitable, and losses have increased over the past 5 years at a rate of -25% per year.

Accelerating Growth: Unable to compare 8NN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8NN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 8NN has a negative Return on Equity (-111.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nordic Nanovector's financial position?


Financial Position Analysis

Short Term Liabilities: 8NN's short term assets (NOK495.3M) exceed its short term liabilities (NOK119.8M).

Long Term Liabilities: 8NN's short term assets (NOK495.3M) exceed its long term liabilities (NOK7.9M).


Debt to Equity History and Analysis

Debt Level: 8NN is debt free.

Reducing Debt: 8NN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 8NN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 8NN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8NN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 8NN has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -32% each year.


Next Steps

Dividend

What is Nordic Nanovector's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8NN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8NN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8NN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8NN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8NN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Lars Nieba

no data

Tenure

Dr. Lars Nieba, PhD, has been Chief Technology Officer of Nordic Nanovector ASA since December 1, 2019 and serves as its Interim Chief Executive Officer since February 26, 2020. Dr. Nieba possess leadershi ...


Leadership Team

NamePositionTenureCompensationOwnership
Tone Kvåle
Chief Financial Officer7.25yrskr2.72m0.29% NOK219.1k
Marco Renoldi
Chief Operating Officer3.67yrskr3.73m0.11% NOK84.8k
Jostein Dahle
Chief Scientific Officerno datakr2.07m0.31% NOK234.8k
Malene Brondberg
Vice President of Investor Relations & Corporate Communications2yrskr2.52m0.014% NOK10.8k
Rita Dege
Chief Human Resources Officerno datakr1.67m0.0072% NOK5.4k
Rosemarie Corrigan
Chief Quality Officer2.25yrskr2.69m0.0037% NOK2.8k
Lars Nieba
Interim CEO & Chief Technology Officerno datano datano data
Fredrik Haavind
Head of Legal & Compliance0.83yrno datano data
Maureen Deehan
Head of Corporate Development & Strategy1.67yrsno datano data
Reza Safaei
Head of Medical Affairs2.58yrsno datano data

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 8NN's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gisela Schwab
Independent Director5yrskr305.00k0.024% NOK18.0k
Per Anders Samuelsson
Director5.25yrskr345.00kno data
Jan Egberts
Chairman of the Board1yrno datano data
Mark Kaminski
Member of Scientific Advisory Board & Member of Clinical Advisory Boardno datano datano data
Stephen Schuster
Member of Scientific Advisory Board4.83yrsno datano data
Timothy Illidge
Chairman of Scientific Advisory Board4.83yrsno datano data
Pier Zinzani
Chairman of Scientific Advisory Board4.83yrsno datano data
Arne Kolstad
Member of Scientific Advisory Board4.83yrsno datano data
Dolores Caballero
Member of Scientific Advisory Board4.83yrsno datano data
Armando Lopez-Guillermo
Member of Scientific Advisory Board4.83yrsno datano data

4.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 8NN's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.


Top Shareholders

Company Information

Nordic Nanovector ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nordic Nanovector ASA
  • Ticker: 8NN
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr866.478m
  • Listing Market Cap: kr75.761m
  • Shares outstanding: 66.14m
  • Website: https://www.nordicnanovector.com

Number of Employees


Location

  • Nordic Nanovector ASA
  • Kjelsåsveien 168 B
  • Oslo
  • Oslo
  • 884
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANOOB (Oslo Bors)YesOrdinary SharesNONOKJul 2014
8NNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2014
0R6YLSE (London Stock Exchange)YesOrdinary SharesGBNOKJul 2014
NANOOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKJul 2014
8NNBRSE (Berne Stock Exchange)YesOrdinary SharesCHCHFJul 2014

Biography

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for haematological cancers. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has research collaborations with Paul Scherrer Institute; Heidelberg Pharma; LegoChemBio; OranoMed; and Norwegian Radium Hospital. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 23:28
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.